Intelligence · Clinical pipeline
Metabolic & obesity · Phase III
Metabolic & obesity programs at Phase III — ClinicalTrials.gov pipeline intelligence.
Programs 11
Quick answer
Metabolic & obesity Phase III programs: NovaPharmaNews indexes 11 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Takeda 35 programs
- NovoThirteen 25 programs
- Eli Lilly and 20 programs
- Regeneron UK 12 programs
- Boehringer Ingelheim 10 programs
- Novo Nordisk A/S 10 programs
- AstraZeneca 9 programs
- LEXICON PHARMACEUTICALS 8 programs
- Eli Lilly and 6 programs
- HOFFMANN-LA ROCHE 6 programs
- George Institute for 5 programs
- Kailera Therapeutics 5 programs
Pipeline programs
-
Botulinum toxin type A
Hospital Authority, Hong Kong
Obesity
1 trial -
Eloralintide
Eli Lilly and Company
Obesity
1 trial -
I8F-MC-GPIX
Eli Lilly Co.
Obesity
1 trial -
J1I-MC-GZBP
Eli Lilly Co.
Obesity
1 trial -
K9531-3107
Kailera Therapeutics
Obesity
1 trial -
KAI-9531
Kailera Therapeutics
Obesity
3 trials -
NN8022-4392
NovoThirteen
Obesity
1 trial -
NN9838-7749
NovoThirteen
Obesity
1 trial -
NN9838-7859
NovoThirteen
Obesity
1 trial -
Setmelanotide
Rhythm Pharmaceuticals Netherlands B.V.
Obesity
1 trial -
lorcaserin
BRIGHT MINDS BIOSCIENCES INC.
Obesity
1 trial
Frequently asked questions
How many metabolic & obesity Phase III programs exist?
11 programs match both the therapeutic area and stage filters in our published index.